180 related articles for article (PubMed ID: 35038597)
1. Do the Favorable Effects of Digoxin and SGLT2 Inhibitors Really Differ in Patients with Heart Failure and a Reduced Ejection Fraction? A Provocative Side-by-Side Examination of Trial Outcomes.
Packer M; Zannad F
J Card Fail; 2022 Apr; 28(4):682-683. PubMed ID: 35038597
[No Abstract] [Full Text] [Related]
2. Impact of SGLT2 Inhibitors on Serum Sodium in Heart Failure With Reduced Ejection Fraction.
Li S; Levy WC
JACC Heart Fail; 2022 May; 10(5):319-320. PubMed ID: 35483793
[No Abstract] [Full Text] [Related]
3. Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.
Kokhan E; Kiyakbaev G; Medovchshikov V
Eur J Heart Fail; 2022 Jul; 24(7):1323-1324. PubMed ID: 35238461
[No Abstract] [Full Text] [Related]
4. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B
Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240
[No Abstract] [Full Text] [Related]
5. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?
Volpe M; Pedicino D
Eur Heart J; 2022 Nov; 43(44):4614-4615. PubMed ID: 36173867
[No Abstract] [Full Text] [Related]
7. Another brick in the wall of cardioprotection? A meta-analysis addressing the effect of sodium-glucose co-transporter 2 inhibitors on left ventricular mass assessed by cardiovascular magnetic resonance in patients with heart failure with reduced ejection fraction.
Patoulias D; Boulmpou A; Doumas M; Papadopoulos CE
J Cardiovasc Med (Hagerstown); 2022 Aug; 23(8):570-572. PubMed ID: 35905005
[No Abstract] [Full Text] [Related]
8. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
9. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
Lan NSR; Fegan PG; Yeap BB; Dwivedi G
ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
[TBL] [Abstract][Full Text] [Related]
10. The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction.
Verma S
Cardiovasc Res; 2020 Jan; 116(1):e8-e10. PubMed ID: 31850505
[No Abstract] [Full Text] [Related]
11. SGLT2 inhibitors - a new pillar for the treatment of heart failure.
Tavačová D; Václavík J
Vnitr Lek; 2021; 67(8):475-478. PubMed ID: 35459367
[TBL] [Abstract][Full Text] [Related]
12. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
Bhatt DL; Verma S; Braunwald E
Cell Metab; 2019 Nov; 30(5):847-849. PubMed ID: 31693879
[TBL] [Abstract][Full Text] [Related]
13. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
14. SGLT-2 inhibition a useful tool in the treatment of heart failure with reduced and preserved ejection fraction.
Slíva J
Vnitr Lek; 2022; 68(6):393-397. PubMed ID: 36316201
[TBL] [Abstract][Full Text] [Related]
15. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.
Genuardi MV; Mather PJ
Ther Adv Cardiovasc Dis; 2021; 15():17539447211002678. PubMed ID: 33779401
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
[TBL] [Abstract][Full Text] [Related]
17. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
18. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Anker SD; Butler J; Filippatos G; Khan MS; Marx N; Lam CSP; Schnaidt S; Ofstad AP; Brueckmann M; Jamal W; Bocchi EA; Ponikowski P; Perrone SV; Januzzi JL; Verma S; Böhm M; Ferreira JP; Pocock SJ; Zannad F; Packer M
Circulation; 2021 Jan; 143(4):337-349. PubMed ID: 33175585
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits.
Dixit NM; Ziaeian B; Fonarow GC
Heart Fail Clin; 2022 Oct; 18(4):587-596. PubMed ID: 36216488
[TBL] [Abstract][Full Text] [Related]
20. Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Burkhoff D; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Gustafsson F; Køber L; Borlaug BA; Schou M; Møller JE
Circ Heart Fail; 2022 Mar; 15(3):e009156. PubMed ID: 34743533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
